Identification of inhibitors to Trypanosoma cruzi Sirtuins based on compounds developed to human enzymes
Arquivos
Data
2020
Autores
Bastos, Tanira Matutino
Soares, Milena Botelho Pereira
Franco, Caio Haddad
Alcântara, Laura
Antonini, Lorenzo
Sabatino, Manuela
Mautone, Nicola
Freitas-Junior, Lucio Holanda
Moraes, Carolina Borsoi
Ragno, Rino
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Chagas disease is an illness caused by the protozoan parasite Trypanosoma cruzi, a↵ecting more than 7 million people in the world. Benznidazole and nifurtimox are the only drugs available for treatment and in addition to causing several side e↵ects, are only satisfactory in the acute phase of the disease. Sirtuins are NAD+-dependent deacetylases involved in several biological processes, which have become drug target candidates in various disease settings. T. cruzi presents two sirtuins, one cytosolic (TcSir2rp1) and the latter mitochondrial (TcSir2rp3). Here, we characterized the e↵ects of human sirtuin inhibitors against T. cruzi sirtuins as an initial approach to develop specific parasite inhibitors. We found that, of 33 compounds tested, two inhibited TcSir2rp1 (15 and 17), while other five inhibited TcSir2rp3 (8, 12, 13, 30, and 32), indicating that specific inhibitors can be devised for each one of the enzymes. Furthermore, all inhibiting compounds prevented parasite proliferation in cultured mammalian cells. When combining the most efective inhibitors with benznidazole at least two compounds, 17 and 32, demonstrated synergistic effects. Altogether, these results support the importance of exploring T. cruzi sirtuins as drug targets and provide key elements to develop specific inhibitors for these enzymes as potential targets for Chagas disease treatment.